Welhart 50mg Capsule contains Mexiletine, a class 1B antiarrhythmic agent used primarily for the management of ventricular arrhythmias. Mexiletine acts by blocking sodium channels in the cardiac cells, thereby stabilizing the cardiac membrane and reducing abnormal electrical activity that can lead to irregular heartbeats. It is indicated for the treatment of life-threatening ventricular arrhythmias, including ventricular tachycardia and premature ventricular contractions, particularly in patients who are unresponsive to or intolerant of other antiarrhythmic therapies. Welhart is administered orally, with the 50mg dosage allowing for flexible titration based on clinical response and patient tolerance. The drug is absorbed rapidly from the gastrointestinal tract, with a bioavailability that supports effective plasma concentrations for arrhythmia control. Common adverse effects may include gastrointestinal disturbances, dizziness, and tremors, while serious side effects such as cardiac conduction abnormalities require close monitoring. Caution is advised in patients with hepatic impairment or pre-existing conduction defects. Mexiletine should be used under strict medical supervision with periodic ECG monitoring to assess therapeutic efficacy and detect potential proarrhythmic effects. Welhart 50mg Capsule offers an essential therapeutic option in the management of ventricular arrhythmias, improving cardiac rhythm stability and patient outcomes.